塞利尼索联合R-CHOP一线治疗双打击/三打击淋巴瘤的2期研究
这项单臂前瞻性2期研究纳入13例新诊断双打击/三打击淋巴瘤患者,接受塞利尼索联合R-CHOP(S-RCHOP)一线治疗。总缓解率100%(完全缓解76.9%),中位随访25.4个月时2年无进展生存率67.7%、总生存率67.1%,但血液学不良事件常见。
要点
- S-RCHOP一线治疗DHL/THL总缓解率100%,完全缓解率76.9%。
- 2年PFS 67.7%、OS 67.1%,1例出现中枢神经系统复发。
- 最常见不良事件为白细胞减少和中性粒细胞减少(各55.1%)。
核心结论
- S-RCHOP在DHL/THL中取得高缓解率,但血液学不良事件频繁,cfDNA监测对疗效评估有参考价值。
研究设计与样本
- 单臂、前瞻性2期研究,2022年5月至2024年8月入组13例新诊断DHL/THL患者。
- 患者接受最多6个21天周期的S-RCHOP,塞利尼索60 mg于第1、8、15天给药。
- 主要终点为总缓解率,次要终点包括PFS、OS、2年内CNS复发率和不良事件。
主要发现
- 13例患者中9例DHL、4例THL,总缓解率100%,完全缓解76.9%,部分缓解23.1%。
- 中位随访25.4个月,2年PFS为67.7%,2年OS为67.1%。
- 1例患者发生CNS复发。
- 最常见全级别不良事件为白细胞减少和中性粒细胞减少(各55.1%)、发热性中性粒细胞减少和乏力(各43.5%)、血小板减少(33.7%)。
- NGS和cfDNA显示BCL6和IGLL5突变常见,治疗后72.7%患者cfDNA转阴且均达PET-CT完全缓解。
临床怎么用
- S-RCHOP可作为DHL/THL一线治疗的探索性方案,但需关注血液学毒性。
- cfDNA监测可能辅助判断治疗反应,但需进一步验证。
局限性
- 单臂设计、样本量小(13例),为初步结果。
- 需进一步研究XPO1抑制联合R-CHOP并优先优化剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Double-hit lymphoma (DHL) and triple-hit lymphoma (THL) are aggressive subtypes of high-grade B-cell lymphoma with poor prognosis. This study evaluated the efficacy and safety of selinexor, a first-in-class oral inhibitor of exportin 1 (XPO1), combined with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; S-RCHOP) as first-line therapy for DHL/THL. This single-arm, prospective phase 2 study enrolled 13 patients from May 2022 to August 2024. Patients received up to 6 21-day cycles of S-RCHOP (selinexor 60 mg on days 1, 8, 15). The primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), central nervous system (CNS) relapse rate within 2 years, and adverse events (AEs). Exploratory analyses included next-generation sequencing (NGS) and circulating cell-free DNA (cfDNA) monitoring. Thirteen patients (9 DHL and 4 THL) were enrolled. ORR was 100% (complete response [CR], 76.9%; partial response, 23.1%). At a median follow-up of 25.4 months, the 2-year PFS and OS were 67.7% and 67.1%, respectively. One patient developed CNS relapse. The most common all-grade AEs included leukopenia and neutropenia (55.1% each), febrile neutropenia and fatigue (43.5% each), and thrombocytopenia (33.7%). NGS and cfDNA revealed frequent BCL6 and IGLL5 mutations. Posttreatment cfDNA negativity was achieved in 72.7% of patients, all of whom were in CR by positron emission tomography-computed tomography. In this study, S-RCHOP achieved high response rates in DHL/THL but was associated with frequent hematologic AEs. cfDNA monitoring provided valuable insights into treatment response. These preliminary findings support further investigation of XPO1 inhibition combined with R-CHOP, with priority given to dose optimization. This trial was registered at www.clinicaltrials.gov as NCT05974085.
引用
- Li C, Chen X, Xu J, et al. Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma. Blood Adv. 2026. PMID: 42480213. doi:10.1182/bloodadvances.2025018580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。